Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 181

1.

Immunohistochemical characterisation of the local immune response in azoxymethane-induced colon tumours in the BDIX inbred rat strain.

Kobaek-Larsen M, Diederichsen A, Agger R, Nissen I, Hokland M, Zeuthen J, Ritskes-Hoitinga J.

APMIS. 2004 Oct;112(10):698-707.

PMID:
15601321
2.

Detection of circulating tumor lysate-reactive CD4+ T cells in melanoma patients.

Ladekarl M, Agger R, Fleischer CC, Hokland M, Hulgaard EF, Kirkin A, von der Maase H, Petersen MS, Rytter C, Zeuthen J, Gundersen HJ.

Cancer Immunol Immunother. 2004 Jun;53(6):560-6. Epub 2004 Feb 25.

PMID:
14985861
3.

Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells.

Diederichsen AC, Hjelmborg Jv, Christensen PB, Zeuthen J, Fenger C.

Cancer Immunol Immunother. 2003 Jul;52(7):423-8. Epub 2003 Apr 15.

PMID:
12695859
4.

Cancer/testis antigens: structural and immunobiological properties.

Kirkin AF, Dzhandzhugazyan KN, Zeuthen J.

Cancer Invest. 2002;20(2):222-36. Review.

PMID:
11901543
5.

Mutational analysis of oncogenes and tumor suppressor genes in human cancer using denaturing gradient gel electrophoresis.

Guldberg P, Grønbaek K, Worm J, thor Straten P, Zeuthen J.

Methods Mol Med. 2002;68:125-39. No abstract available.

PMID:
11901498
6.

Multiple mechanisms of immune evasion can coexist in melanoma tumor cell lines derived from the same patient.

Real LM, Jimenez P, Kirkin A, Serrano A, García A, Cantón J, Zeuthen J, Garrido F, Ruiz-Cabello F.

Cancer Immunol Immunother. 2001 Jan;49(11):621-8.

PMID:
11225993
7.

The V410I (G1228A) variant of the caspase-10 gene is a common polymorphism of the Danish population.

Grønbaek K, Dalby T, Zeuthen J, Ralfkiaer E, Guidberg P.

Blood. 2000 Mar 15;95(6):2184-5. No abstract available.

8.

T-cell receptor clonotype mapping using denaturing gradient gel electrophoresis : analysis of clonal T-cell responses in melanoma.

Straten PT, Becker JC, Zeuthen J, Guldberg P.

Methods Mol Med. 2001;61:339-51. doi: 10.1385/1-59259-145-0:339.

PMID:
22323267
9.

Comparative delineation of T cell clonotypes in coexisting syngeneic B16 melanoma.

Moerch U, Schrama D, Guldberg P, Seremet T, Zeuthen J, Becker JC, thor Straten P.

Cancer Immunol Immunother. 2000 Oct;49(8):426-32.

PMID:
11043849
10.

Aberrant p27Kip1 promoter methylation in malignant melanoma.

Worm J, Bartkova J, Kirkin AF, Straten P, Zeuthen J, Bartek J, Guldberg P.

Oncogene. 2000 Oct 19;19(44):5111-5.

11.

Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma.

Grønbaek K, de Nully Brown P, Møller MB, Nedergaard T, Ralfkiaer E, Møller P, Zeuthen J, Guldberg P.

Leukemia. 2000 Oct;14(10):1727-35.

PMID:
11021747
12.

Lectin purified human class I MHC-derived peptides: evidence for presentation of glycopeptides in vivo.

Kastrup IB, Stevanovic S, Arsequell G, Valencia G, Zeuthen J, Rammensee HG, Elliott T, Haurum JS.

Tissue Antigens. 2000 Aug;56(2):129-35.

PMID:
11019912
13.

Escape mechanisms in tumor immunity: a year 2000 update.

Pawelec G, Heinzel S, Kiessling R, Müller L, Ouyang Q, Zeuthen J.

Crit Rev Oncog. 2000;11(2):97-133. Review.

PMID:
11005508
14.

Amino acid substitutions in the melanoma antigen recognized by T cell 1 peptide modulate cytokine responses in melanoma-specific T cells.

Nielsen MB, Kirkin AF, Loftus D, Nissen MH, Rivoltini L, Zeuthen J, Geisler C, Odum N.

J Immunother. 2000 Jul-Aug;23(4):405-11.

PMID:
10916749
15.

Poor correspondence between predicted and experimental binding of peptides to class I MHC molecules.

Andersen MH, Tan L, Søndergaard I, Zeuthen J, Elliott T, Haurum JS.

Tissue Antigens. 2000 Jun;55(6):519-31.

PMID:
10902608
16.

Tumor infiltrating lymphocytes in melanoma comprise high numbers of T-cell clonotypes that are lost during in vitro culture.

thor Straten P, Kirkin AF, Siim E, Dahlström K, Drzewiecki KT, Seremet T, Zeuthen J, Becker JC, Guldberg P.

Clin Immunol. 2000 Aug;96(2):94-9.

PMID:
10900156
17.

Primary cutaneous B-cell lymphoma: a clinical, histological, phenotypic and genotypic study of 21 cases.

Grønbaek K, Møller PH, Nedergaard T, Thomsen K, Baadsgaard O, Hou-Jensen K, Zeuthen J, Guldberg P, Ralfkiaer E.

Br J Dermatol. 2000 May;142(5):913-23.

PMID:
10809848
18.

Cell cycle arrest by the PTEN tumor suppressor is target cell specific and may require protein phosphatase activity.

Hlobilkova A, Guldberg P, Thullberg M, Zeuthen J, Lukas J, Bartek J.

Exp Cell Res. 2000 May 1;256(2):571-7.

PMID:
10772829
19.

Expression of CD94/NKG2 subtypes on tumor-infiltrating lymphocytes in primary and metastatic melanoma.

Vetter CS, Straten PT, Terheyden P, Zeuthen J, Bröcker EB, Becker JC.

J Invest Dermatol. 2000 May;114(5):941-7.

20.

Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules.

Berke Z, Andersen MH, Pedersen M, Fugger L, Zeuthen J, Haurum JS.

Leukemia. 2000 Mar;14(3):419-26.

PMID:
10720136
21.

Phase I study of single, escalating doses of a superantigen-antibody fusion protein (PNU-214565) in patients with advanced colorectal or pancreatic carcinoma.

Nielsen SE, Zeuthen J, Lund B, Persson B, Alenfall J, Hansen HH.

J Immunother. 2000 Jan;23(1):146-53.

PMID:
10687147
23.

Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies.

Birck A, Ahrenkiel V, Zeuthen J, Hou-Jensen K, Guldberg P.

J Invest Dermatol. 2000 Feb;114(2):277-80.

24.

Accumulation of identical T cells in melanoma and vitiligo-like leukoderma.

Becker JC, Guldberg P, Zeuthen J, Bröcker EB, Straten PT.

J Invest Dermatol. 1999 Dec;113(6):1033-8.

25.

Characterisation of tumour infiltrating lymphocytes and correlations with immunological surface molecules in colorectal cancer.

Diederichsen AC, Zeuthen J, Christensen PB, Kristensen T.

Eur J Cancer. 1999 May;35(5):721-6.

PMID:
10505031
26.
27.

In situ T cells in melanoma.

thor Straten P, Becker JC, Guldberg P, Zeuthen J.

Cancer Immunol Immunother. 1999 Oct;48(7):386-95. Review.

PMID:
10501852
28.

Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL.

Andersen MH, Bonfill JE, Neisig A, Arsequell G, Sondergaard I, Valencia G, Neefjes J, Zeuthen J, Elliott T, Haurum JS.

J Immunol. 1999 Oct 1;163(7):3812-8. Erratum in: J Immunol 2000 May 15;164(10):5531.

29.

An assay for peptide binding to HLA-Cw*0102.

Andersen MH, Søndergaard I, Zeuthen J, Elliott T, Haurum JS.

Tissue Antigens. 1999 Aug;54(2):185-90.

PMID:
10488746
30.

Establishment of gp100 and MART-1/Melan-A-specific cytotoxic T lymphocyte clones using in vitro immunization against preselected highly immunogenic melanoma cell clones.

Kirkin AF, thor Straten P, Hansen MR, Barfoed A, Dzhandzhugazyan KN, Zeuthen J.

Cancer Immunol Immunother. 1999 Aug;48(5):239-46.

PMID:
10478640
31.

Presentation of cytosolic glycosylated peptides by human class I major histocompatibility complex molecules in vivo.

Haurum JS, Høier IB, Arsequell G, Neisig A, Valencia G, Zeuthen J, Neefjes J, Elliott T.

J Exp Med. 1999 Jul 5;190(1):145-50.

32.

In situ T cell responses against melanoma comprise high numbers of locally expanded T cell clonotypes.

thor Straten P, Guldberg P, Grønbaek K, Hansen MR, Kirkin AF, Seremet T, Zeuthen J, Becker JC.

J Immunol. 1999 Jul 1;163(1):443-7.

33.

Cells and cytokines in immunotherapy and gene therapy of cancer.

Pawelec G, Rees RC, Kiessling R, Madrigal A, Dodi A, Baxevanis C, Gambacorti-Passerini C, Masucci G, Zeuthen J.

Crit Rev Oncog. 1999;10(1-2):83-127. Review.

PMID:
10327211
34.

Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/STK11, in malignant melanoma.

Guldberg P, thor Straten P, Ahrenkiel V, Seremet T, Kirkin AF, Zeuthen J.

Oncogene. 1999 Mar 4;18(9):1777-80.

35.

The immunogenic properties of human melanomas and melanoma-associated antigens recognized by cytotoxic T lymphocytes.

Zeuthen J, Dzhandzhugazyan K, Hansen MR, Kirkin AF.

Bratisl Lek Listy. 1998 Aug-Sep;99(8-9):426-34. Review.

PMID:
9810766
36.

Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity.

Grønbaek K, Straten PT, Ralfkiaer E, Ahrenkiel V, Andersen MK, Hansen NE, Zeuthen J, Hou-Jensen K, Guldberg P.

Blood. 1998 Nov 1;92(9):3018-24.

37.

Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells.

Li K, Adibzadeh M, Halder T, Kalbacher H, Heinzel S, Müller C, Zeuthen J, Pawelec G.

Cancer Immunol Immunother. 1998 Sep;47(1):32-8.

PMID:
9755876
38.

Melanoma-associated antigens recognized by cytotoxic T lymphocytes.

Kirkin AF, Dzhandzhugazyan K, Zeuthen J.

APMIS. 1998 Jul;106(7):665-79. Review.

PMID:
9740504
39.

Detection and characterization of alpha-beta-T-cell clonality by denaturing gradient gel electrophoresis (DGGE).

thor Straten P, Barfoed A, Seremet T, Saeterdal I, Zeuthen J, Guldberg P.

Biotechniques. 1998 Aug;25(2):244-50.

PMID:
9714884
40.

Concurrent disruption of cell cycle associated genes in mantle cell lymphoma: a genotypic and phenotypic study of cyclin D1, p16, p15, p53 and pRb.

Grønbaek K, Nedergaard T, Andersen MK, thor Straten P, Guldberg P, Møller P, Zeuthen J, Ebbe Hansen N, Hou-Jensen K, Ralfkiaer E.

Leukemia. 1998 Aug;12(8):1266-71.

PMID:
9697882
41.

Ecto-ATP diphosphohydrolase/CD39 is overexpressed in differentiated human melanomas.

Dzhandzhugazyan KN, Kirkin AF, thor Straten P, Zeuthen J.

FEBS Lett. 1998 Jul 3;430(3):227-30.

42.

A comparison of flow cytometry and immunohistochemistry in human colorectal cancers.

Diederichsen AC, Hansen TP, Nielsen O, Fenger C, Jensenius JC, Christensen PB, Kristensen T, Zeuthen J.

APMIS. 1998 May;106(5):562-70.

PMID:
9674894
43.

Activation of preexisting T cell clones by targeted interleukin 2 therapy.

Straten PT, Guldberg P, Seremet T, Reisfeld RA, Zeuthen J, Becker JC.

Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8785-90.

44.

Sticky and smelly issues: lessons on tumour cell and leucocyte trafficking, gene and immunotherapy of cancer.

Alexandroff AB, McIntyre CA, Porter JC, Zeuthen J, Vile RG, Taub DD.

Br J Cancer. 1998 Jun;77(11):1806-11. Review.

45.
46.

Flow cytometric investigation of immune-response-related surface molecules on human colorectal cancers.

Diederichsen AC, Stenholm AC, Kronborg O, Fenger C, Jensenius JC, Zeuthen J, Christensen PB, Kristensen T.

Int J Cancer. 1998 Jun 19;79(3):283-7. Erratum in: Int J Cancer 1998 Oct 23;79(5):551. Ostenhom AC [corrected to Stenholm AC].

47.

Immunisation of colorectal cancer patients with autologous tumour cells.

Diederichsen AC, Stenholm AC, Kronborg O, Fenger C, Jensenius JC, Zeuthen J, Kristensen T, Christensen PB.

Oncol Rep. 1998 Jul-Aug;5(4):823-6.

PMID:
9625825
48.

The immunogenic properties of melanoma-associated antigens recognized by cytotoxic T lymphocytes.

Kirkin AF, Dzhandzhugazyan K, Zeuthen J.

Exp Clin Immunogenet. 1998;15(1):19-32. Review.

PMID:
9619397
49.

Alterations of the MMAC1/PTEN gene in lymphoid malignancies.

Grønbaek K, Zeuthen J, Guldberg P, Ralfkiaer E, Hou-Jensen K.

Blood. 1998 Jun 1;91(11):4388-90. No abstract available.

50.

Detection of mutations in GC-rich DNA by bisulphite denaturing gradient gel electrophoresis.

Guldberg P, Grønbak K, Aggerholm A, Platz A, thor Straten P, Ahrenkiel V, Hokland P, Zeuthen J.

Nucleic Acids Res. 1998 Mar 15;26(6):1548-9.

Supplemental Content

Loading ...
Support Center